• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非酒精性脂肪性肝病中的肠道微生物组。

The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.

机构信息

Department of Internal Medicine, Virginia Commonwealth University School of Medicine, MCV Box 980341, Richmond, VA 23298-0341, USA.

Department of Internal Medicine, Virginia Commonwealth University School of Medicine, MCV Box 980341, Richmond, VA 23298-0341, USA.

出版信息

Clin Liver Dis. 2018 Feb;22(1):121-132. doi: 10.1016/j.cld.2017.08.009.

DOI:10.1016/j.cld.2017.08.009
PMID:29128052
Abstract

Nonalcoholic fatty liver disease is the most common cause of chronic liver disease in North America and is growing as a cause of chronic liver disease in many other parts of the world as well. It has 2 principal clinical-pathologic phenotypes: (1) nonalcoholic fatty liver and (2) nonalcoholic steatohepatitis. The development of both phenotypes is tightly linked to excess body weight and insulin resistance. This review discusses the emerging tools for the analysis of the microbiome, their limitations, and the existing literature with respect to the intestinal microbiome and their role in nonalcoholic fatty liver.

摘要

非酒精性脂肪性肝病是北美最常见的慢性肝病病因,在世界上许多其他地区也逐渐成为慢性肝病的病因之一。它有两种主要的临床病理表型:(1)非酒精性脂肪肝和(2)非酒精性脂肪性肝炎。这两种表型的发展都与超重和胰岛素抵抗密切相关。这篇综述讨论了用于分析微生物组的新兴工具、它们的局限性以及关于肠道微生物组及其在非酒精性脂肪性肝病中的作用的现有文献。

相似文献

1
The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的肠道微生物组。
Clin Liver Dis. 2018 Feb;22(1):121-132. doi: 10.1016/j.cld.2017.08.009.
2
Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis.非酒精性脂肪性肝病、非酒精性脂肪性肝炎和肝硬化中的益生菌
J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S28-32. doi: 10.1097/MCG.0000000000000347.
3
[Gut microbiota and nonalcoholic steatohepatitis].[肠道微生物群与非酒精性脂肪性肝炎]
Nihon Yakurigaku Zasshi. 2018;152(4):187-193. doi: 10.1254/fpj.152.187.
4
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.肠道微生物群和Toll样受体在非酒精性脂肪性肝病中的作用。
World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381.
5
Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?肠道微生物群的变化与酒精性和非酒精性肝病:是原因还是结果?
Gastroenterology. 2016 Jun;150(8):1745-1755.e3. doi: 10.1053/j.gastro.2016.02.073. Epub 2016 Mar 4.
6
Obesity, fatty liver disease and intestinal microbiota.肥胖、脂肪肝疾病与肠道微生物群
World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.
7
Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease.与儿童非酒精性脂肪性肝病患者的脂肪性肝炎和中重度纤维化相关的微生物组特征。
Gastroenterology. 2019 Oct;157(4):1109-1122. doi: 10.1053/j.gastro.2019.06.028. Epub 2019 Jun 27.
8
Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.肠道微生物群作为非酒精性脂肪性肝病炎症的驱动因素。
Mediators Inflamm. 2018 Jan 31;2018:9321643. doi: 10.1155/2018/9321643. eCollection 2018.
9
Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.蛋氨酸-胆碱缺乏饮食诱导的非酒精性脂肪性肝炎发生过程中肠道微生物组和代谢组的动态变化。
World J Gastroenterol. 2018 Jun 21;24(23):2468-2481. doi: 10.3748/wjg.v24.i23.2468.
10
The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.非酒精性脂肪性肝病的肠道微生物群:当前方法及其解读
Hepatol Int. 2015 Jul;9(3):406-15. doi: 10.1007/s12072-015-9640-2. Epub 2015 Jun 12.

引用本文的文献

1
Understanding crosstalk between the gut and liver microbiome: pathogenesis to therapeutic approaches in liver cancer.了解肠道和肝脏微生物群之间的串扰:肝癌的发病机制与治疗方法
Cancer Cell Int. 2025 Jul 29;25(1):291. doi: 10.1186/s12935-025-03840-9.
2
Blood bacterial DNA signatures in a prospective cohort of patients with MASLD cirrhosis.非酒精性脂肪性肝炎肝硬化患者前瞻性队列中的血液细菌DNA特征
Hepatol Commun. 2025 Jun 9;9(7). doi: 10.1097/HC9.0000000000000722. eCollection 2025 Jul 1.
3
Gut Microbiome and Hepatic Transcriptomic Determinants of HCC Development in Mice with Metabolic Dysfunction-Associated Steatohepatitis.
代谢功能障碍相关脂肪性肝炎小鼠中肝癌发生的肠道微生物群和肝脏转录组学决定因素
J Hepatocell Carcinoma. 2024 Oct 3;11:1891-1905. doi: 10.2147/JHC.S485532. eCollection 2024.
4
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism.细菌生物膜在代谢相关脂肪性肝炎中的作用及对肝纤维化的保护作用及其氨基酸代谢的关系
Gut Microbes. 2024 Jan-Dec;16(1):2399260. doi: 10.1080/19490976.2024.2399260. Epub 2024 Sep 6.
5
Gut phageome in Mexican Americans: a population at high risk for metabolic dysfunction-associated steatotic liver disease and diabetes.墨西哥裔美国人的肠道噬菌体组:一个代谢功能障碍相关脂肪性肝病和糖尿病高危人群。
mSystems. 2024 Sep 17;9(9):e0043424. doi: 10.1128/msystems.00434-24. Epub 2024 Aug 21.
6
The emerging role of the gut mycobiome in liver diseases.肠道真菌组在肝脏疾病中的新兴作用。
Gut Microbes. 2023 Jan-Dec;15(1):2211922. doi: 10.1080/19490976.2023.2211922.
7
Ameliorates High-Carbohydrate Diet-Induced Hepatic Lipid Accumulation and Oxidative Stress by Upregulating Uridine Synthesis.通过上调尿苷合成改善高碳水化合物饮食诱导的肝脏脂质积累和氧化应激。
Antioxidants (Basel). 2022 Jun 24;11(7):1238. doi: 10.3390/antiox11071238.
8
Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs.非酒精性脂肪性肝炎(NASH)与动脉粥样硬化:阐释其病理生理学、关联及基于肠促胰岛素药物的作用
Antioxidants (Basel). 2022 May 27;11(6):1060. doi: 10.3390/antiox11061060.
9
Effect of Probiotics Therapy on Nonalcoholic Fatty Liver Disease.益生菌疗法对非酒精性脂肪性肝病的影响。
Comput Math Methods Med. 2022 May 30;2022:7888076. doi: 10.1155/2022/7888076. eCollection 2022.
10
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC.遗传学、免疫和营养促进非酒精性脂肪性肝炎向肝癌的转变。
Biomedicines. 2021 Oct 23;9(11):1524. doi: 10.3390/biomedicines9111524.